- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
A signal transuction by the EGFR system strictly depends on dimerisation, inactivation of only one receptor molecule in heterodimers my not be sufficient for optimal inhibition of tumour cell growth and survival. Combined EGFR/HER1 and HER2 inhibition may thus provide a more complete block of EGFR/HER/ErbB family signalling.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
